| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 04/15/2009 | EP1385547B1 Antibody which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 04/15/2009 | EP1352085B1 P2y purinergic receptor expression for identifying preneoplastic and neoplastic states |
| 04/15/2009 | EP1334196B1 Genomic fragment of streptococcus suis and clinical uses thereof |
| 04/15/2009 | CN101410528A Methods for modulating mannose content of recombinant proteins |
| 04/15/2009 | CN101410414A Synergistic compositions for treating HIV-1 |
| 04/15/2009 | CN101410413A Anti-EPHRINB2 antiboies and methods using same |
| 04/15/2009 | CN101410412A Generation of heavy-chain only antibodies in transgenic animals |
| 04/15/2009 | CN101410137A Anti-IGF-1R human monoclonal antibody formulation |
| 04/15/2009 | CN101410136A Concentrate of immunoglobulins and F(ab)'2 and/or Fab fragments specific of an arbovirus as medicine |
| 04/15/2009 | CN101407546A Human anti-human tumor necrosis factor-alpha single chain antibody |
| 04/15/2009 | CN101407545A 131I labeled anti-tumor humanized monoclonal antibody 1E2 and use thereof |
| 04/15/2009 | CN101407544A Anti-Golgi apparatus protein monoclonal antibody and use |
| 04/15/2009 | CN101407542A Preparations and uses of streptomycin-carrier protein coupled product and streptomycin antibody |
| 04/15/2009 | CN101407541A Modified allosteric type cyclic citrulline polypeptide, and fusion protein, antibody and reagent kit thereof |
| 04/15/2009 | CN101407501A Preparation of 5-methyl morpholine-3-amino-2-oxazolidinone derivative hapten, antigen and antibody |
| 04/15/2009 | CN101407480A Preparation of semicarbazide derivative hapten, antigen and antibody |
| 04/15/2009 | CN101407458A I type pyrethroid universal hapten compound and synthetic method thereof |
| 04/15/2009 | CN101406696A Vaccine comprising a tick cement protein |
| 04/15/2009 | CN100478689C Polypeptide and use thereof |
| 04/15/2009 | CN100478357C Ofloxacin couple and its preparing method and use |
| 04/15/2009 | CN100478355C New human protein with mouse NIH/3T3 cell transformation improving function and its code sequence |
| 04/15/2009 | CN100478354C Novel human protein with cancer inhibiting function and its code sequence |
| 04/15/2009 | CN100478029C Immunomodulatory human MHC class II antigen-binding polypeptides |
| 04/14/2009 | US7517976 proteins and/or polypeptides encoded by DNA isolated from rna viruses, used as vaccines, for detection and treatment of swine infected with PRRSV |
| 04/14/2009 | US7517971 Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity |
| 04/14/2009 | US7517967 Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| 04/14/2009 | US7517966 antibodies that bind polypeptides that are prefrentially expressed by all mature NK cells, used for medical diagnosis, prevention of viral and microbial infections, and as antitumor agents |
| 04/14/2009 | US7517965 Non-neutralizing anti-aPC antibodies |
| 04/14/2009 | US7517964 RS7 antibodies |
| 04/14/2009 | US7517963 Tumour necrosis factor binding ligands |
| 04/14/2009 | US7517962 TWEAK receptor |
| 04/14/2009 | US7517866 LIM mineralization protein splice variants |
| 04/14/2009 | US7517855 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof |
| 04/14/2009 | US7517672 Nucleic acids encoding mammalian T-type calcium channels |
| 04/14/2009 | US7517670 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 04/14/2009 | US7517666 Using urease as tool in identifying modulators of bacterial propagation; enzyme inhibitors |
| 04/14/2009 | US7517663 Rabbit monoclonal antibody against Id1 protein |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | US7517533 Pseudomonas aeruginosa antigens |
| 04/14/2009 | US7517527 Immunotoxin with in vivo T cell suppressant activity and methods of use |
| 04/14/2009 | US7517526 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 04/14/2009 | US7517525 Methods of inhibiting amyloid toxicity |
| 04/14/2009 | US7517524 Monoclonal antibody or an antigen-binding fragment thereof which binds to human VEGF-B (vascular endothelial growth factor) produced by hybridoma; neovascularization diseases; antitumor, anticarcinogenic, antiinflammatory, and antimetastasis agents; rheumatoid arthritis; angiogenesis inhibitors |
| 04/14/2009 | US7517523 Anti-MIF antibodies |
| 04/14/2009 | CA2559998C Rapamycin conjugates and antibodies |
| 04/14/2009 | CA2439182C Novel calcium-independent phospholipases a2, genes thereof and promoter of the same |
| 04/14/2009 | CA2318576C Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| 04/14/2009 | CA2304980C Immunoassay to detect herpesvirus specific igm |
| 04/14/2009 | CA2259657C Identification of a transforming fragment of herpes simplex type 2 and detection thereof in clinical specimens |
| 04/14/2009 | CA2225852C Anti-fas ligand antibody and assay method using the anti-fas ligand antibody |
| 04/14/2009 | CA2208237C Nuclear protein serine/threonine kinases |
| 04/14/2009 | CA2201887C Patched genes and their use |
| 04/14/2009 | CA2130900C Therapeutic domains of von willebrand factor |
| 04/09/2009 | WO2009046313A2 Novel compositions and methods for stimulating erythropoiesis in a mammal |
| 04/09/2009 | WO2009046294A2 Treatment of proliferative disorders using antibodies to psma |
| 04/09/2009 | WO2009046174A1 Methods and compositions for detecting and treating end-stage cardiomyopathy using claudin-5 |
| 04/09/2009 | WO2009046123A2 Nlrr-1 antagonists and uses thereof |
| 04/09/2009 | WO2009045075A2 A monoclonal antibody specific to human embryonic stem cell, a hybridoma secreting the same and a method for detecting or isolating non-differenced embryonic stem cell |
| 04/09/2009 | WO2009044561A1 ANTI-proNT/NMN MONOCLONAL ANTIBODY |
| 04/09/2009 | WO2009044284A1 Antibodies specific for human hepcidin |
| 04/09/2009 | WO2009044158A2 Inhibitors and uses |
| 04/09/2009 | WO2009044153A2 Inhibitors and uses |
| 04/09/2009 | WO2009043933A1 Il-23 antibodies |
| 04/09/2009 | WO2009043922A2 Extracellular targets for alzheimer's disease |
| 04/09/2009 | WO2009043490A1 Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof |
| 04/09/2009 | WO2009043173A1 Cc2d2a gene mutations associated with joubert syndrome and diagnostic methods for identifying the same |
| 04/09/2009 | WO2009043166A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/09/2009 | WO2009043103A1 Therapeutic antibody purification method and method of use |
| 04/09/2009 | WO2009010290A3 Engineered anti-alpha v- integrin hybrid antibodies |
| 04/09/2009 | WO2009007427A3 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 04/09/2009 | WO2009000099A3 Methods of modifying antibodies, and modified antibodies with improved functional properties |
| 04/09/2009 | WO2008151819A3 Treatment of tumors using specific anti-l1 antibody |
| 04/09/2009 | WO2008142164A3 Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| 04/09/2009 | WO2008141285A3 Methods for early diagnosis of kidney disease |
| 04/09/2009 | WO2008135259A3 Antibody molecule composition |
| 04/09/2009 | WO2008106200A3 Human anti-ip-10 antibodies and uses thereof |
| 04/09/2009 | WO2008088849A9 Inflammation treatment, detection and monitoring via trem-1 |
| 04/09/2009 | WO2008070666A3 Compositions and methods to treat cancer with cpg rich dna and cupredoxins |
| 04/09/2009 | WO2008070303A3 Therapeutics to inhibit mll-menin interaction for treating leukemia |
| 04/09/2009 | WO2007098297A3 Method for diagnosing and treating kidney cancer |
| 04/09/2009 | WO2007092196A3 Compositions and methods for treating myeloid proliferative disorders |
| 04/09/2009 | WO2007041171A3 Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells |
| 04/09/2009 | WO2006084092A3 Antibodies to oncostatin m receptor |
| 04/09/2009 | WO2006083957A3 Tat-001 and methods of assessing and treating cancer |
| 04/09/2009 | WO2006063031A3 Allelic variants of human factor viii |
| 04/09/2009 | WO2006044333A3 Methods and materials for the inhibition of transplant rejection |
| 04/09/2009 | WO2006039407A3 Validation of tssk family members and tsks as male contraceptive targets |
| 04/09/2009 | WO2006031524A3 Early detection of hemangiosarcoma and angiosarcoma |
| 04/09/2009 | WO2005121175A3 Env polypeptide complexes and methods of use |
| 04/09/2009 | WO2005115457A3 Combined active and passive targeting of biologically active agents |
| 04/09/2009 | WO2005113833A3 Polymorphism in tryptophan hydroxylase-2 controls brain serotonin synthesis |
| 04/09/2009 | WO2005112998A3 Compositions and methods for preventing erythropoietin-associated hypertension |
| 04/09/2009 | WO2005086775A3 Lumen-exposed molecules and methods for targeted delivery |
| 04/09/2009 | WO2005077071A3 Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| 04/09/2009 | WO2005072507A3 Biomarker detection in circulating cells |
| 04/09/2009 | WO2005032496A3 Hydrolases, nucleic acids encoding them and mehods for making and using them |
| 04/09/2009 | WO2004113361A3 Novel prokineticin receptor isoforms and methods of use |
| 04/09/2009 | WO2004101511A3 Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases |
| 04/09/2009 | US20090094715 Methods of use of antibodies with reduced immunogenicity or toxicity |
| 04/09/2009 | US20090094708 Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives |